Delek US Holdings has surged past its own analyst targets after a stunning 215% one-year run, and its CEO just said all options are on the table. The question is whether any strategic buyer…
Energy Transfer's co-founder just made a nine-figure bet on his own partnership, and the timing of the purchase raises a question every income investor should sit with before deciding what it means.
Micron has turned nearly every skeptic into a believer after a historic run, but two rigorous forecasting models now point in opposite directions on where the stock goes from here. Which one should a…
Oracle trades nearly $100 below Wall Street's consensus target, yet the forces that crushed the stock over the past year have not touched its hyperscaler peers. Whether that gap is a value opportunity or…
Two nearly identical ETFs built on the same structure pay out weekly cash, yet one is quietly eating its own investors alive while the other holds up. The difference comes down to a single…
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those…
JEPQ and HYG both deliver monthly income, but they are built on completely different bets, and when credit markets crack, only one of those bets pays off while the other quietly bleeds principal.
A late-night tariff pause between the U.S. and Canada left nothing signed and everything at stake, but three stocks are already pricing in a deal that could still fall apart before the ink dries.
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war…
GM's relentless buyback machine crushed Ford and the S&P 500 for over a year, but something shifted in 2026 and now the tortoise is quietly pulling ahead. Before you bet on which automaker wins…
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Alibaba and NetEase both report earnings the same morning, forcing a direct choice between two very different China tech bets. Analyst sentiment, price targets, and crowd prediction markets all point in conflicting directions, and…
Aurora Innovation operates the only driverless Class 8 trucks running at scale on U.S. public roads, and that monopoly position is drawing serious attention from some of the heaviest hitters in freight and tech.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a…
Target and Lowe's both report earnings on the same morning, putting two very different bets on the American consumer head to head. Which one actually deserves your retirement capital before the opening bell?
Berkshire Hathaway's new CEO just made the firm's biggest single-quarter bet in years, and the stock he chose reveals exactly how he plans to run the empire differently than Buffett did.
Bill Ackman just made Visa a major new bet after the stock trailed the S&P 500 for five straight years. Whether that lag signals a coiled spring or a structural problem depends on threats…
Corning's CEO went on national television and told investors that tariffs are essentially a non-issue for the company, citing two specific figures about its U.S. manufacturing footprint. The explanation traces back to a philosophy…
A newly public biotech is betting its entire future on a single antibody platform designed to silence the cytokine scientists call the itch cytokine, and its pipeline already stretches from skin disease into inflammatory…
Bill Ackman once fled Netflix at a loss, so his decision to buy back in now raises a pointed question: does he see a genuine turnaround forming in a stock that has badly lagged…
